-
Scipher Medicine Presents New Data at the European League Against Rheumatism (EULAR) 2021 Further Validating PrismRA® Test -
Scipher Medicine and Leading Medical Researchers in Network and Data Science Compress Time to Identify Covid-19 Treatments from Years to Months -
Scipher Applies SpectraTM Platform to Discover Drugs Targeting Autoimmune Patients Refractory to Existing Therapies -
Scipher Medicine Announces $82 Million Financing -
WellDyne Partners with Scipher Medicine to Improve Patient Outcomes and Lower Costs for Rheumatoid Arthritis Care -
Scipher Medicine Brings Precision Medicine Platform to Patient-Centered MIT Initiative -
New Study Demonstrates Clinical Utility of PrismRA Test in Guiding Therapy Selection for Rheumatoid Arthritis Patients -
Mariann Byerwalter joins Scipher Medicine’s Board of Advisors -
18th U.S. Surgeon General Joins Scipher Medicine -
Scipher Medicine and Ambry Genetics Partner to Bring Precision Medicine Test for Rheumatoid Arthritis to Market -
Scipher Medicine and Galapagos sign collaboration in inflammatory bowel disease -
Scipher Medicine Announces Publication of Clinical Study Validating PrismRA, a Blood Test Predicting Non-Response to TNF Inhibitor Therapies in Patients with Rheumatoid Arthritis -
Scipher Medicine Welcomes Jerry Conway, Appointed Senior Vice President of Market Access -
Scipher Medicine Welcomes Chief Technology Officer -
Scipher Medicine Announces Investment By Optum Ventures Focused on Improving Patient Outcomes